A Medical Device Daily
Mednetworld.com (MEDNET; Minneapolis), a provider of Nationwide Health Information Network (NHIN) connectivity and Health Information Exchange (HIE) solutions, and Bostech (Indianapolis), the healthcare interoperability company behind ChainBuilder Connect, reported a managed service HIE solution for Nationwide Health Information Network, or NHIN, connectivity.
The joint product offering, called the Managed Service NHIN Gateway, is a comprehensive managed service that enables HIE building, clinical data interoperability, and NHIN connectivity. Previously, healthcare providers had limited choices for off-the-shelf HIE-NHIN connectivity and interoperability solutions. With the MEDNET – Bostech Managed Service NHIN Gateway, providers have complete data interoperability, along with HIE and NHIN connectivity, as a managed service with premium service and support.
"Healthcare customers looking for off-the-shelf, ready to go, interoperable NHIN solutions can now simply pick up the phone and call us," said MEDNET's CEO John Fraser. "HIEs can now focus on mission critical work, relying on our experience to manage their interoperability and connectivity needs."
"This important partnership will make it easy for healthcare providers to access an advanced, integrated HIE and NHIN solution," said Brad Bostic, Bostech's CEO. "This alliance enables our healthcare customers to quickly and efficiently form HIE communities that connect to the NHIN."
In other agreements and contracts news:
• PerkinElmer (Corning, New York) and Corning (Corning, New York) reported that the two companies have entered into a strategic agreement to advance the development of label-free detection technologies. The agreement will allow Corning and PerkinElmer to combine their expertise in optical label-free and multi-modality detection to develop and deliver detection platforms for life sciences research. Label-free detection is an enabling technology targeted at addressing many of the challenges in early stage lead optimization in the drug discovery process.
• Micronics (Redmond, Washington) has entered into a license agreement with Biosearch Technologies (Novato, California) for the right to make, have made, use and sell Micronics' products that incorporate Biosearch's fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics' infectious disease tests for sale in underdeveloped countries.